Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $13.
Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $13.